Clinical trials Brief October 18, 2026, 8:00 PM ET

AbbVie announces data to be presented at 2026 ESMO Congress

AbbVie today announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology Congress in Madrid, Spain. The presentations cover investigational assets such as Temab-A, ABBV-706, ABBV-969, ABBV-1480, alveltamig, EmrelisTM and Elahere.

Primary source

Company press release (PR Newswire), October 18, 2026

AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio

Read the source: AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio prnewswire.com

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation